Other languages IDEAYA Biosciences, Inc.

Equities

IDYA

US45166A1025

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
38.01 ^USD	-4.09%		+3.99%	+6.83%

Jun. 04	Stifel Adjusts Price Target on IDEAYA Biosciences to $63 From $55, Maintains Buy Rating	MT
Jun. 03	IDEAYA Biosciences, Inc. Announces Results for darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma At Asco and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IDEAYA Biosciences, Inc. Announces Results for darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma At Asco and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study	Jun. 03
Ideaya Biosciences Insider Sold Shares Worth $1,032,884, According to a Recent SEC Filing	Jun. 03
IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024	May. 28
Ideaya Biosciences Insider Sold Shares Worth $7,397,291, According to a Recent SEC Filing	May. 16
IDEAYA Biosciences Shares Fall After Q1 Loss	May. 07
IDEAYA Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07
IDEAYA Biosciences, Inc. Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer	Apr. 22
IDEAYA Biosciences, Merck Sign Deal to Evaluate IDE161 in Combination with Keytruda to Treat Endometrial Cancer Patients	Mar. 12
IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer	Mar. 12
IDEAYA Biosciences Q4 Loss Widens, Revenue Declines	Feb. 20
IDEAYA Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 20
IDEAYA Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 20
Ideaya Biosciences Insider Sold Shares Worth $4,495,550, According to a Recent SEC Filing	Feb. 12
Ideaya Biosciences Insider Sold Shares Worth $350,371, According to a Recent SEC Filing	Dec. 19
Ideaya Biosciences Insider Sold Shares Worth $2,627,618, According to a Recent SEC Filing	Dec. 19
Ideaya Biosciences, Inc. Announces Clinical Study Collaboration with Gilead Sciences, Inc. to Evaluate Trodelvy and Ide397 Combination in Mtap-Deletion Bladder Cancer	Dec. 04
IDEAYA Biosciences, Inc. Enters into an Office Lease Agreement with AAT TORREY 13-14, LLC to Expand Its Current Office Space in San Diego	Nov. 17
Ideaya Biosciences Insider Sold Shares Worth $155,360, According to a Recent SEC Filing	Nov. 07
IDEAYA Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07
IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline	23-10-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages IDEAYA Biosciences, Inc.

Equities

IDYA

US45166A1025

Other languages

Filters